J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayThe FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share XJ&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayhttps://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/
